References in periodicals archive ?
today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.
We also have a new CD heading for clinical phase 1, MIV-711, a cathepsin K inhibitor for treating skeletal disorders.
a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of neuropathic pain, autoimmune diseases, liver diseases and dermatological diseases, today announced that Thomas J.
We note that it is possible that when a sample is hemolyzed, intracellular proteases such as cathepsins may be released into the plasma from erythrocytes (4).
The study indicates Cathepsin B as a new target for therapeutic inhibition of AB production and subsequent improved memory function," said Hook.
The reactivities of these MAbs were further studied with cathepsin G-ACT captured on the solid phase by a polyclonal anti-cathepsin G antibody.
Washington, June 2 (ANI): A research team has developed an experiment that reliably detects and quantifies mature cathepsin K - an enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis.
Many studies have implicated endopeptidases cathepsin D, B, and L in the development, growth, and dissemination of breast cancer (BC) [4] (1, 2).
In other disease areas, we are developing Cathepsin K against skeletal disorders and Cathepsin S against neuropathic pain.
In addition, Quest continues to hold the cathepsin K intellectual property licensed by Celera to Merck for the drug odanacatib.
They went on to identify components of the complex signalling network linking ErbB2 and cathepsin expression with cancer invasiveness.
Coverage includes salivary biomarkers, tumor markers in pseudopodia for invasive migration, intraocular lymphoma markers, serum tumor markers in breast cancer, diagnostic classification using gene expression profiling in AML, tumor antigens as markers of minimal residual disease in acute myeloid leukemia, activity and expression of dipeptidyl peptidase IV and cathepsin H in human cutaneous melanoma compared to other common cancers, ovarian cancer detection, comparison of the prognostic association of nucleolar size between uveal and conjunctival melanoma, biomarkers of hepatocellular carcinoma, cell adhesive markers in metastasizing colorectal carcinoma, and fetal hemoglobin as an oncofetal marker.